Previous studies have shown that the combination of decitabine (DAC), an inhibitor of DNMTs, with the traditional chemotherapy drug oxaliplatin yielded satisfactory anticancer effects both in vitro and in vivo experiments by reversal of hypermethylation in the promoter of SLC22A2, thereby increasing the expression of OCT2 in renal cancer cells 8, 9. Here, SLC22A2 is linked to renal carcinoma.